(Q43562054)

24 November 2017

Role of cholecystokinin in the reduction of endomorphin-2-induced antinociception in diabetic mice (English)

1 reference

24 November 2017

1 reference

J Kamei

1

1 reference

24 November 2017

K Zushida

series ordinal

2

1 reference

24 November 2017

H Nagase

series ordinal

3

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

European Journal of Pharmacology

24 November 2017

1 reference

24 November 2017

416

1 reference

24 November 2017

1-2

1 reference

24 November 2017

95-99

1 reference

Cholecystokinin in the central nervous system: A minireview

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Potentiation of morphine and clomipramine analgesia by cholecystokinin -B antagonist CI-988 in diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Evidence for the Neuropeptide Cholecystokinin as an Antagonist of Opiate Analgesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

The role of spinal cholecystokinin B receptors in thermal allodynia and hyperalgesia in diabetic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Role of spleen or spleen products in the deficiency in morphine-induced analgesia in diabetic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by μ-opioid agonists, but not by δ- and κ-opioid agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

The antinociceptive effects of endomorphin-1 and endomorphin-2 in diabetic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

The ascent of cholecystokinin (CCK) — From gut to brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Possible involvement of spinal protein kinase C in thermal allodynia and hyperalgesia in diabetic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Role of intracellular calcium in thermal allodynia and hyperalgesia in diabetic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Cholecystokinin and morphine analgesia: variations on a theme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by beta-endorphin and morphine administered intracerebroventricularly in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

Cholecystokinin octapeptide antagonized opioid analgesia mediated by mu- and kappa- but not delta-receptors in the spinal cord of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900886-X

10.1016/S0014-2999(01)00886-X

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference